Prognostic Significance of

Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung / drug therapy Disease-Free Survival ErbB Receptors / genetics Female Humans Male Mutation / genetics Protein Kinase Inhibitors / administration & dosage Treatment Outcome
Epidermal growth factor receptor gene mutation anti-tumor effects best supportive care non-small-cell lung cancer prognosis

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
May 2021
Historique:
received: 08 03 2021
revised: 25 03 2021
accepted: 29 03 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 14 5 2021
Statut: ppublish

Résumé

The significance of epidermal growth factor receptor (EGFR) mutation in untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to determine the significance of EGFR mutation in patients who received best supportive care (BSC) alone, and compare the outcomes of only EGFR- tyrosine kinase inhibitors (TKI)-treated vs. BSC patients. Between April 1991-August 2018, 1,197 patients diagnosed with unresectable NSCLC at our institutions were enrolled in the study. Among 226 patients who underwent EGFR mutation analysis and received BSC alone, 35 and 191 did and did not harbor the mutation, and the median survival times (MST) did not differ significantly between these groups. A comparison of only EGFR-TKI-treated and BSC patients with EGFR mutation revealed that the former had a three times longer MST than the latter. Our results may help explain the benefit of EGFR-TKI for patients who would be directed towards BSC.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
The significance of epidermal growth factor receptor (EGFR) mutation in untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to determine the significance of EGFR mutation in patients who received best supportive care (BSC) alone, and compare the outcomes of only EGFR- tyrosine kinase inhibitors (TKI)-treated vs. BSC patients.
PATIENTS AND METHODS METHODS
Between April 1991-August 2018, 1,197 patients diagnosed with unresectable NSCLC at our institutions were enrolled in the study.
RESULTS RESULTS
Among 226 patients who underwent EGFR mutation analysis and received BSC alone, 35 and 191 did and did not harbor the mutation, and the median survival times (MST) did not differ significantly between these groups. A comparison of only EGFR-TKI-treated and BSC patients with EGFR mutation revealed that the former had a three times longer MST than the latter.
CONCLUSION CONCLUSIONS
Our results may help explain the benefit of EGFR-TKI for patients who would be directed towards BSC.

Identifiants

DOI: 10.21873/anticanres.15047 PMID: 33952497
pubmed: 33952497
pii: 41/5/2661
doi: 10.21873/anticanres.15047
doi:

Substances chimiques

Protein Kinase Inhibitors 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2661-2667

Informations de copyright

Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Takeshi Masuda (T)

Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan; ta-masuda@hiroshima-u.ac.jp.

Y U Wakabayashi (YU)

Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Taku Nakashima (T)

Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Yoshifumi Nishimura (Y)

Department of Respiratory Internal Medicine, Higashihiroshima Medical Center, Higashihiroshima, Japan.

Kiyofumi Shimoji (K)

Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Kakuhiro Yamaguchi (K)

Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Shinjiro Sakamoto (S)

Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Yasushi Horimasu (Y)

Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Shintaro Miyamoto (S)

Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Tadashi Senoo (T)

Department of Respiratory Internal Medicine, Kure Medical Center, Kure, Japan.

Hiroshi Iwamoto (H)

Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Shinichiro Ohshimo (S)

Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Kazunori Fujitaka (K)

Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Hironobu Hamada (H)

Department of Physical Analysis and Therapeutic Sciences, Hiroshima University, Hiroshima, Japan.

Noboru Hattori (N)

Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Prognostic Significance of
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Prognostic Significance of
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Prognostic Significance of
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Prognostic Significance of
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Prognostic Significance of
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic Significance of
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Prognostic Significance of
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Prognostic Significance of
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Prognostic Significance of